Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
ResMed Wide Awake
Aug 09 2010
Sleep disorder group ResMed delivered a solid result according to brokers, with most remaining positive on the expectation earnings momentum will continue in coming quarters.
Macquarie’s Conviction And More FY11 Previews
Aug 06 2010
Macquarie’s conviction calls and broker views on the contractor, transport and healthcare sectors.
Big Pharma Eyeing Mesoblast?
Jul 27 2010
Mesoblast has been recording good Phase II trials results in bone marrow transplantation and Southern Cross Equities suggests this could make it a target of Big Pharma.
CSL Gaining At Baxter’s Expense
Jul 26 2010
The latest report from Baxter of the US leads brokers to suggest CSL is gaining market share at that company’s expense, though opinions remain divided on the value in CSL at current levels.
More Reporting Season Previews
Jul 22 2010
Brokers discuss healthcare while JP Morgan looks for surprises and RBS points out where $37bn in franking credits could be accessed.
Previewing FY10 Results And FY11 Outlook
Jul 21 2010
Brokers are now making assessments of how the FY10 earning season will fare and what FY11 might bring.
A Guide To The Australian Reporting Season
Jul 20 2010
Australian companies begin reporting FY10 results next week. FNArena provides some useful tips for the small investor – what to look out for, and what traps not to fall into.
CSL Facing Blood Pressure Test
Jul 15 2010
Another big guidance downgrade from a CSL competitor suggests a global oversupply of plasma will make for a tough FY11.
Question Marks Remain For Oz Pathology Sector
Jul 14 2010
Both credit Suisse and Deutsche bank have reviewed the Australian pathology sector to account for changes in market conditions and expectations.
Value In Equities Even As Earnings Revised Lower
Jul 07 2010
While corporate earnings in Australia and globally are likely to be revised lower in coming months there still appears to be value in equities at current levels.
